Acute Respiratory Failure: When to Use Nasal Cannula, High-Flow, BiPAP, or Invasive Ventilation

Bottom line

Initial workup

• Bedside: continuous pulse oximetry and telemetry, full vitals, and a work-of-breathing assessment (accessory muscle use, paradoxical abdominal motion, ability to speak in full sentences).
• Chest radiograph (or point-of-care ultrasound or CT when the diagnosis is unclear or the patient is not responding) to define the extent of disease; multilobar infiltrates are a severity marker.
• Gases and labs: an ABG for the P/F ratio and pH once on oxygen (a VBG is adequate only for trending CO2 and pH), plus CBC, CMP, lactate, blood and sputum cultures, respiratory viral/influenza PCR, and urinary antigens in severe pneumonia.
• Score severity and triage: count the IDSA/ATS minor criteria (RR ≥ 30, P/F ≤ 250, multilobar infiltrates, confusion, uremia, leukopenia, thrombocytopenia, hypothermia, hypotension requiring fluids); three or more, or a need for vasopressors or intubation, defines severe disease and ICU-level care.
• Screen for mimics and co-contributors: heart failure (BNP, echocardiogram), pulmonary embolism, effusion or empyema, and ARDS.

Oxygen delivery devices: FiO2 delivered and flow limits

• Why low-flow devices hit a ceiling: a dyspneic patient's peak inspiratory flow is roughly 30–60 L/min or more, far above what a cannula or mask supplies, so every breath entrains room air and dilutes the delivered FiO2. The figures below are approximations that vary substantially with minute ventilation, mouth breathing, and mask fit.
• Standard nasal cannula: 1–6 L/min. FiO2 rises about 4% per liter above room air — 1 L/min ≈ 0.24, 2 L/min ≈ 0.28, 4 L/min ≈ 0.36, 5 L/min ≈ 0.40, 6 L/min ≈ 0.44. Flows above 6 L/min are not useful: the nasopharyngeal reservoir is already full at about 6 L/min, so extra flow only adds nasal drying and discomfort without raising FiO2.
• Simple face mask: 5–10 L/min for FiO2 of roughly 0.35–0.60. Never run it below 5 L/min, because lower flows allow CO2 rebreathing from the mask reservoir.
• Non-rebreather reservoir mask: 10–15 L/min for FiO2 of approximately 0.60–0.90 (a true 1.0 is rarely achieved because of mask leak and entrainment). Keep the bag inflated at all times and treat it as a short-term bridge while deciding on escalation.
• Venturi (air-entrainment) mask: delivers a set FiO2 largely independent of breathing pattern — typically 24% at 2–4 L/min, 28% at 4–6 L/min, 31% at 6–8 L/min, 35% at 8–10 L/min, 40% at 10–12 L/min, and 60% at 12–15 L/min (check the flow printed on each valve). Increase the set flow above the labeled minimum when the patient is tachypneic. It is the device of choice when a known, stable FiO2 matters, including controlled oxygen in CO2 retainers.
• Heated humidified high-flow nasal cannula: flows of 30–60 L/min (devices reach about 60–70 L/min) with FiO2 set independently from 0.21 to 1.0, gas heated to 34–37 °C and fully humidified. Because flow meets or exceeds inspiratory demand, the set FiO2 approximates the delivered FiO2; it also washes out nasopharyngeal dead space and generates modest PEEP (about 2–5 cmH2O at high flows with the mouth closed). Typical start: 40–50 L/min at FiO2 0.5–0.6; wean FiO2 first, then flow.
• Non-invasive ventilation: CPAP 5–10 cmH2O, or BiPAP with EPAP 5–10 and IPAP 10–16 cmH2O (a driving pressure of about 5–10), with FiO2 0.21–1.0. In pneumonia-related hypoxemia without cardiogenic edema or COPD it is less established than high-flow and risks large tidal volumes, so use it only in a monitored setting with a defined 1–2 hour reassessment.
• Invasive mechanical ventilation: FiO2 1.0 initially, then titrate rapidly to the lowest FiO2 that keeps SpO2 about 92–96%, PEEP of at least 5 cmH2O and higher per a PEEP/FiO2 table if ARDS physiology develops, with lung-protective tidal volumes of 4–8 mL/kg predicted body weight and a plateau pressure below 30 cmH2O.
• Stepping up: SpO2 below 92% despite nasal cannula at 6 L/min → Venturi 40–60% or a non-rebreather at 10–15 L/min, reassessed within 30–60 minutes; a need for FiO2 ≥ 0.5 by mask, RR above 30, or accessory muscle use → high-flow nasal cannula in a monitored bed; high-flow at 50–60 L/min with FiO2 above 0.6, or a ROX index below 3.85 at 2, 6, or 12 hours → urgent ICU consult and strong consideration of intubation.

Acute management: the escalation ladder

• Conventional oxygen first: nasal cannula 2–6 L/min titrated to SpO2 92–96% (avoid hyperoxia). If the FiO2 need rises, step up to a Venturi mask or non-rebreather while arranging definitive support; conventional oxygen suffices only for mild hypoxemia with preserved respiratory mechanics.
• High-flow nasal cannula when the patient needs high flows or FiO2 (roughly > 40–50 L/min equivalent, P/F 200–300, or SpO2 persisting in the high 80s on conventional oxygen) or has ongoing tachypnea and work of breathing. Typical start: flow 40–60 L/min, FiO2 titrated to SpO2 92–96%, temperature 34–37 °C. HFNC delivers a stable FiO2, dead-space washout, and modest PEEP, and is the preferred non-invasive modality for de novo hypoxemic failure.
• Do not default to BiPAP or CPAP for de novo hypoxemic pneumonia. NIV is first-line for hypercapnic failure and hypoventilation physiology; reserve it for those indications (hypercapnic acidosis, COPD or obesity hypoventilation, cardiogenic pulmonary edema → CPAP or BiPAP) and, if trialed, use short, closely supervised trials with reassessment at 1–2 hours. A typical BiPAP start is IPAP 10–12 / EPAP 4–5 cmH2O, titrating IPAP for ventilation and EPAP/FiO2 for oxygenation.
• Treat the cause in parallel: empiric antibiotics within the first hours by pneumonia severity and MRSA/Pseudomonas risk, oseltamivir if influenza is suspected, fluids or vasopressors as needed, drainage of a significant parapneumonic effusion, and fever and pain control to reduce respiratory drive.
• Adjuncts: awake self-proning in cooperative, hemodynamically stable hypoxemic patients; incentive spirometry, mobilization, and secretion clearance; avoid sedatives that blunt respiratory drive.
• Level of care moves with the device: request a rapid-response or ICU evaluation early, and move to step-down or ICU whenever HFNC or NIV is required — do not run either unmonitored on a general medicine floor.

Inpatient and longitudinal management

• Wean deliberately once gas exchange improves: HFNC → conventional nasal cannula when FiO2 ≤ 0.40 and flow ≤ 20–30 L/min with stable SpO2 and respiratory rate, then trial off oxygen with ambulatory saturation testing.
• Continue pneumonia care: narrow antibiotics by culture and clinical response, switch IV to oral once hemodynamically stable and tolerating oral intake, and treat for a minimum of 5 days and until clinically stable.
• Routine inpatient care: VTE prophylaxis, glucose monitoring if steroids are used, aspiration precautions, early mobility and physiotherapy, and delirium screening.
• Before discharge: smoking cessation, pneumococcal, influenza, and COVID vaccination, inhaler and device teaching if obstructive disease is identified, and heart failure optimization if it contributed.

Monitoring and disposition

• Continuous pulse oximetry and cardiac monitoring; reassess respiratory rate, work of breathing, mental status, and FiO2 requirement at least hourly during escalation and every 4 hours once stable.
• Repeat an ABG 1–2 hours after any change in support and whenever mental status or respiratory rate worsens; track P/F and ROX trends rather than single values.
• Level of care: ICU for intubation, vasopressors, or ≥ 3 IDSA/ATS minor severity criteria; step-down or ICU for HFNC or NIV.
• Discharge readiness: afebrile, hemodynamically stable, RR < 24, SpO2 ≥ 90–92% on room air (or stable home oxygen) including with ambulation, tolerating oral antibiotics and intake, and at baseline mental status.
• Follow-up within 7 days with primary care; repeat imaging in 6–12 weeks if there are risk factors for malignancy or a non-resolving infiltrate; arrange home oxygen with ambulatory testing if hypoxemia persists.

Escalate care if

• SpO2 remains < 90–92% or RR stays ≥ 30 with accessory muscle use after 1–2 hours of optimized conventional oxygen — escalate to HFNC and move to a monitored bed.
• On HFNC at FiO2 ≥ 0.60–1.0 and flow 50–60 L/min with persistent hypoxemia, worsening tachypnea, or a deteriorating ROX index (SpO2/FiO2 ÷ RR; < 4.88 at 2, 6, and 12 hours suggests failure) — intubate rather than prolong non-invasive support; HFNC failure is an indication for invasive ventilation.
• NIV is trialed and after 1–2 hours there is no improvement in pH, PaCO2, respiratory rate, or dyspnea, tidal volumes are large, or the mask is not tolerated — intubate promptly.
• Hypercapnic failure develops (rising PaCO2 with pH < 7.35) — start BiPAP and titrate IPAP for ventilation; if pH < 7.25 or worsening despite NIV, or the patient becomes somnolent — intubate.
• Altered mental status, inability to protect the airway, copious secretions, hemodynamic instability or shock, or imminent arrest — intubate without a non-invasive trial.
• Once intubated: lung-protective ventilation (6 mL/kg predicted body weight, plateau pressure ≤ 30 cmH2O, PEEP titrated to oxygenation), lower respiratory tract samples for culture, and prone positioning if P/F < 150 with ARDS physiology.

Duration

Oxygen support continues until SpO2 is ≥ 90–92% on room air at rest and with ambulation. Antibiotics for pneumonia run a minimum of 5 days and until clinical stability, extended for complications.

Caveats

• Avoid NIV as default therapy in de novo hypoxemic respiratory failure without hypercapnia — delayed intubation worsens outcomes; NIV is primarily indicated for hypercapnic or hypoventilatory failure.
• NIV is contraindicated with depressed mental status, inability to protect the airway, vomiting or high aspiration risk, facial trauma, hemodynamic instability, or a need for emergent intubation.
• Avoid excessive oxygen targets (SpO2 > 96%) given the risks of hyperoxia; in any possible chronic CO2 retention, target 88–92%.
• HFNC and NIV should not be managed on an unmonitored general ward; escalate the level of care with the device.
• The FiO2 figures quoted for low-flow devices are approximations that vary with minute ventilation, mouth breathing, and mask fit; a simple mask below 5 L/min risks CO2 rebreathing, and a non-rebreather must keep its reservoir bag inflated.
• This overview assumes a hemodynamically stable patient with no immediate airway threat; shock or obtundation mandates immediate intubation regardless of SpO2.

References

1. Diagnosis and Treatment of Adults with Community-acquired Pneumonia (ATS/IDSA). Am J Respir Crit Care Med. (2019) · Primary guideline
2. Managing ICU surge during the COVID-19 crisis: rapid guidelines. · Primary guideline“We suggest that hospitals develop and implement protocols for intubation as well as the use of high-flow nasal oxygen (HFNO) and noninvasive ventilation (NIV) in order to reduce the need for intubation.”
3. High-Flow Nasal Cannula in Patients Awaiting Lung Transplant: Evidence, Clinical Applications, and Outcomes. (2026) · Narrative review“HFNC becomes an important therapeutic option when patients require high oxygen flow rates—typically exceeding 40–50 L/min—yet continue to demonstrate suboptimal oxygenation, such as a PaO2/FiO2 ratio in the range of 200–300 or persistent oxygen saturations in the high 80s on conventional oxygen therapy.”